<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02766686</url>
  </required_header>
  <id_info>
    <org_study_id>STR - ProtoChoice-P - 2015</org_study_id>
    <nct_id>NCT02766686</nct_id>
  </id_info>
  <brief_title>Preference-based Comparative Study on Definitive Radiotherapy of Prostate Cancer With Protons</brief_title>
  <acronym>ProtoChoice-P</acronym>
  <official_title>Preference-based Comparative Study on Definitive Radiotherapy of Prostate Cancer With Protons in Standard Fractionation and Standard Dosage</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Technische Universität Dresden</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>German Consortium for Translational Cancer Research</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Center for Radiation Research in Oncology Dresden/Heidelberg</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Radiation Oncology Working Group of the German Cancer Society</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Technische Universität Dresden</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      ProtoChoice-P is a prospective multicenter trial to evaluate proton therapy in patients&#xD;
      suffering from prostate cancer. Primary aim of the study is a decrease of moderate or severe&#xD;
      genito-urinary or intestinal side effects (Common Terminology Criteria for Adverse Events&#xD;
      (CTCAE) 4.0 grade 2 or higher) by the use of proton therapy. Secondary endpoints contain&#xD;
      assessment of quality of life, biochemical recurrence and recurrence free survival as well as&#xD;
      overall survival and economic comparison between photon and proton therapy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The hypothesis of the study is a 7.5% decrease of combined genito-urinary and intestinal side&#xD;
      effects from 15% with photon therapy to 7.5% by the use of protons. With an alpha of 0.05 and&#xD;
      80% power it is therefore necessary to treat 131 patients with protons to detect such&#xD;
      difference. With an estimated drop-out rate of 10% 146 patients have to be recruited to the&#xD;
      proton arm. As randomization to photon or proton therapy is not possible in a multicenter&#xD;
      setting with only few proton facilities available patients treated with photons will be&#xD;
      prospectively matched to their proton counterparts. Stratification criteria will include:&#xD;
      Age, high dose volume, androgen deprivation, history of surgery, obstructive disease,&#xD;
      increased risk for rectal bleeding, socio-economic criteria and use of rectal balloon during&#xD;
      radiotherapy. Comparison of the primary endpoint will be restricted to patients without&#xD;
      irradiation of lymphatic drainage.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2016</start_date>
  <completion_date type="Anticipated">August 2023</completion_date>
  <primary_completion_date type="Anticipated">August 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cumulative incidence of moderate/ severe side effects</measure>
    <time_frame>after 2 years ( measured from the first day of treatment)</time_frame>
    <description>≥ grade 2 by CTCAE combined for genito-urinary and gastrointestinal side effects</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">146</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>Radiotherapy with protons</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Proton radiotherapy 74-80 Gray equivalent (GyE), 2Gy per fraction, 5 fractions peer week</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Radiotherapy with photons</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Photon-Intensity-Modulated Radiation Therapy (IMRT) without lymph drainage vessels, 74-80 Gy, 2Gray (Gy) per fraction, 5 fractions peer week</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Radiotherapy with photons with lymph drainage vessels</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Photon-IMRT with lymph drainage vessels, 74-80 Gy, 2Gy per fraction, 5 fractions peer week</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Radiotherapy with protons</intervention_name>
    <arm_group_label>Radiotherapy with protons</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Radiotherapy with photons</intervention_name>
    <arm_group_label>Radiotherapy with photons</arm_group_label>
    <arm_group_label>Radiotherapy with photons with lymph drainage vessels</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  life expectancy ≥ 10 years&#xD;
&#xD;
          -  adenocarcinoma of the prostate confirmed by punch biopsy&#xD;
&#xD;
          -  locally limited to locally advanced adenocarcinomas without evidence of distant&#xD;
             metastases i.e. T1-3b N0-1 M0&#xD;
&#xD;
          -  stage-related indicated neoadjuvant / adjuvant androgen deprivation possible&#xD;
             (neoadjuvant ≤ 6 months)&#xD;
&#xD;
          -  good general condition (ECOG performance status 0 - 1)&#xD;
&#xD;
          -  marker seed implantation before irradiation (optional) or possibility of Image-guided&#xD;
             Radiation Therapy (IGRT) by CT&#xD;
&#xD;
          -  adequate compliance for follow-up&#xD;
&#xD;
          -  written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  distant metastases&#xD;
&#xD;
          -  previous radiotherapy of the lesser pelvis&#xD;
&#xD;
          -  previous or concomitant other malignant disease except when there is no impact on&#xD;
             treatment or follow-up of the prostate cancer&#xD;
&#xD;
          -  participation in another clinical study, if it's excluded by the study protocols&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tobias Hölscher, Dr.</last_name>
    <role>Study Chair</role>
    <affiliation>University Hospital Carl Gustav Carus, Department of Radiation Therapy and Radiation Oncology, German Consortium for Translational Cancer Research (DKTK)</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Tobias Hölscher, Dr.</last_name>
    <phone>+49 351 458 2238</phone>
    <email>str.studien@uniklinikum-dresden.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Hölscher Tobias, Dr.</last_name>
    <phone>+49 351 458 2238</phone>
    <email>str.studien@uniklinikum-dresden.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University Hospital Carl Gustav Carus, Department of Radiotherapy and Radiation Oncology</name>
      <address>
        <city>Dresden</city>
        <zip>01307</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Baumann, Prof.</last_name>
      <phone>+49 351 458 2238</phone>
      <email>str.studien@uniklinikum-dresden.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Klinikum rechts der Isar, Technische Universität München</name>
      <address>
        <city>Munich</city>
        <zip>81675</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Stephanie Combs, Prof.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsklinik für Radioonkologie, Universitätsklinikum Tübingen</name>
      <address>
        <city>Tubingen</city>
        <zip>72076</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Zips Daniel, Prof.</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>May 9, 2016</study_first_submitted>
  <study_first_submitted_qc>May 9, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 10, 2016</study_first_posted>
  <last_update_submitted>August 18, 2021</last_update_submitted>
  <last_update_submitted_qc>August 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Technische Universität Dresden</investigator_affiliation>
    <investigator_full_name>Tobias Hölscher</investigator_full_name>
    <investigator_title>Dr. Tobias Hölscher</investigator_title>
  </responsible_party>
  <keyword>Prostate cancer</keyword>
  <keyword>proton radiotherapy</keyword>
  <keyword>photon radiotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

